# Cartesian Therapeutics Maintains 'Buy' Rating

> Cartesian Therapeutics keeps 'Buy' rating with Descartes-08 cell therapy progress and CAR-T agreement.
- Title: Cartesian Therapeutics Maintains 'Buy' Rating · Seekingalpha
- Summary: Cartesian Therapeutics keeps 'Buy' rating with Descartes-08 cell therapy progress and CAR-T agreement. Cartesian Therapeutics maintains 'Buy' rating due to…
- Keywords: cartesian, descartes-08, car-t, rnac, myositis, blf, phase-3, aurora, money, business, Therapeutics, Maintains
- Source: Seekingalpha — https://seekingalpha.com/article/4959569-cartesian-maintaining-buy-descartes-08-mg-data-release-and-car-t-agreement
- Author: Terry Chrisomalis
- Published: 2026-10-29T18:54:07+00:00
- Read time: 1 min
- Topics: cartesian, descartes-08, car-t, rnac, myositis, blf, phase-3, aurora, money, business
## Rating Update
Cartesian Therapeutics maintains a 'Buy' rating driven by advancing Descartes-08 cell therapy programs and late-stage clinical catalysts.
## Clinical Timeline
Topline results from phase 3 AURORA study in AChR Ab+ Myasthenia Gravis expected in Q1 2027 with potential BLA filing in mid-2027.
## Strategic Expansion
RNAC expands Descartes-08 into myositis indications and pursues in vivo CAR-T approach via WestGene licensing agreement with initial data in H1 2027.
## Financial Position
Strong cash position of $149.3M as of June 2026 provides operational runway into 2028 for clinical and strategic initiatives.
## Key takeaway

Cartesian Therapeutics maintains 'Buy' rating due to Descartes-08 cell therapy advancements and CAR-T agreement.